These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15284258)

  • 21. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.
    Campiglio M; Locatelli A; Olgiati C; Normanno N; Somenzi G; Viganò L; Fumagalli M; Ménard S; Gianni L
    J Cell Physiol; 2004 Feb; 198(2):259-68. PubMed ID: 14603528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
    Smith J
    Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer.
    Tan AR; Yang X; Berman A; Zhai S; Sparreboom A; Parr AL; Chow C; Brahim JS; Steinberg SM; Figg WD; Swain SM
    Clin Cancer Res; 2004 Aug; 10(15):5038-47. PubMed ID: 15297405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
    Cappuzzo F; Magrini E; Ceresoli GL; Bartolini S; Rossi E; Ludovini V; Gregorc V; Ligorio C; Cancellieri A; Damiani S; Spreafico A; Paties CT; Lombardo L; Calandri C; Bellezza G; Tonato M; Crinò L
    J Natl Cancer Inst; 2004 Aug; 96(15):1133-41. PubMed ID: 15292385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.
    Baselga J; Albanell J; Ruiz A; Lluch A; Gascón P; Guillém V; González S; Sauleda S; Marimón I; Tabernero JM; Koehler MT; Rojo F
    J Clin Oncol; 2005 Aug; 23(23):5323-33. PubMed ID: 15939921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Cohen EE; Rosen F; Stadler WM; Recant W; Stenson K; Huo D; Vokes EE
    J Clin Oncol; 2003 May; 21(10):1980-7. PubMed ID: 12743152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy.
    Felip E; Rojo F; Reck M; Heller A; Klughammer B; Sala G; Cedres S; Peralta S; Maacke H; Foernzler D; Parera M; Möcks J; Saura C; Gatzemeier U; Baselga J
    Clin Cancer Res; 2008 Jun; 14(12):3867-74. PubMed ID: 18559607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
    Xia W; Mullin RJ; Keith BR; Liu LH; Ma H; Rusnak DW; Owens G; Alligood KJ; Spector NL
    Oncogene; 2002 Sep; 21(41):6255-63. PubMed ID: 12214266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
    Haura EB; Zheng Z; Song L; Cantor A; Bepler G
    Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling.
    Normanno N; Campiglio M; Maiello MR; De Luca A; Mancino M; Gallo M; D'Alessio A; Menard S
    Breast Cancer Res Treat; 2008 Nov; 112(1):25-33. PubMed ID: 18060492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients.
    Kallergi G; Agelaki S; Kalykaki A; Stournaras C; Mavroudis D; Georgoulias V
    Breast Cancer Res; 2008; 10(5):R80. PubMed ID: 18822183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
    Asanuma H; Torigoe T; Kamiguchi K; Hirohashi Y; Ohmura T; Hirata K; Sato M; Sato N
    Cancer Res; 2005 Dec; 65(23):11018-25. PubMed ID: 16322251
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options.
    Scartozzi M; Bearzi I; Berardi R; Mandolesi A; Pierantoni C; Cascinu S
    Br J Cancer; 2007 Jul; 97(1):92-7. PubMed ID: 17579627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
    Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of epithelial growth factor receptor (EGFR) kinase inhibitors on genetically reconstituted mouse mammary glands.
    Roth DR; Roman D; Cozens R; Brandt R; Seewald W; Greiner B; Wenger F; Mamom T; Germann PG
    Exp Toxicol Pathol; 2003 Nov; 55(4):237-45. PubMed ID: 14703768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.
    Albanell J; Codony-Servat J; Rojo F; Del Campo JM; Sauleda S; Anido J; Raspall G; Giralt J; Roselló J; Nicholson RI; Mendelsohn J; Baselga J
    Cancer Res; 2001 Sep; 61(17):6500-10. PubMed ID: 11522647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erlotinib prevents pulmonary metastasis in curatively resected breast carcinoma using a mouse model.
    Choi YJ; Nam SJ; Son MJ; Kim DK; Kim JH; Yang JH; Kim MH; Song HS; Nam DH; Bang SI
    Oncol Rep; 2006 Jul; 16(1):119-22. PubMed ID: 16786133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma.
    Tsien CI; Nyati MK; Ahsan A; Ramanand SG; Chepeha DB; Worden FP; Helman JI; D'Silva N; Bradford CR; Wolf GT; Lawrence TS; Eisbruch A
    Head Neck; 2013 Sep; 35(9):1323-30. PubMed ID: 22907806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.